Janus kinase inhibitors and biologics for treatment of livedoid vasculopathy: a systematic review
Purpose: Livedoid vasculopathy (LV) is a chronic microvascular thrombosis disorder with an unclear pathogenesis, potentially involving hypercoagulability and inflammation. This systematic review aims to evaluate the efficacy and safety of Janus kinase (JAK) inhibitors and biologics in the treatment...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2025.2451804 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594243963584512 |
|---|---|
| author | Yu Liu Tingting Li Wei Shi |
| author_facet | Yu Liu Tingting Li Wei Shi |
| author_sort | Yu Liu |
| collection | DOAJ |
| description | Purpose: Livedoid vasculopathy (LV) is a chronic microvascular thrombosis disorder with an unclear pathogenesis, potentially involving hypercoagulability and inflammation. This systematic review aims to evaluate the efficacy and safety of Janus kinase (JAK) inhibitors and biologics in the treatment of LV.Materials and methods: A comprehensive search was conducted in PubMed, EMBASE, and the Cochrane Library on June 10, 2024, to identify relevant studies evaluating the use of JAK inhibitors and biologics in LV treatment.Results: A total of 15 articles were included in the review. Among the 41 patients treated with biologics and JAK inhibitors, 36 (87.8%) showed positive clinical responses, including significant improvements in pain relief. TNF-α inhibitors were the most commonly used monotherapy, followed by JAK inhibitors. Adverse events were infrequent, suggesting that these treatments generally have a favorable safety profile.Conclusions: JAK inhibitors and biologics appear to be safe and effective alternatives for managing refractory LV. These findings provide a foundation for future studies to further validate their clinical effectiveness and long-term safety. |
| format | Article |
| id | doaj-art-d1e2a43cd89e4d6d9e5bd84e593b9608 |
| institution | Kabale University |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-d1e2a43cd89e4d6d9e5bd84e593b96082025-01-20T01:09:39ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532025-12-0136110.1080/09546634.2025.2451804Janus kinase inhibitors and biologics for treatment of livedoid vasculopathy: a systematic reviewYu Liu0Tingting Li1Wei Shi2Department of Dermatology, Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, ChinaPurpose: Livedoid vasculopathy (LV) is a chronic microvascular thrombosis disorder with an unclear pathogenesis, potentially involving hypercoagulability and inflammation. This systematic review aims to evaluate the efficacy and safety of Janus kinase (JAK) inhibitors and biologics in the treatment of LV.Materials and methods: A comprehensive search was conducted in PubMed, EMBASE, and the Cochrane Library on June 10, 2024, to identify relevant studies evaluating the use of JAK inhibitors and biologics in LV treatment.Results: A total of 15 articles were included in the review. Among the 41 patients treated with biologics and JAK inhibitors, 36 (87.8%) showed positive clinical responses, including significant improvements in pain relief. TNF-α inhibitors were the most commonly used monotherapy, followed by JAK inhibitors. Adverse events were infrequent, suggesting that these treatments generally have a favorable safety profile.Conclusions: JAK inhibitors and biologics appear to be safe and effective alternatives for managing refractory LV. These findings provide a foundation for future studies to further validate their clinical effectiveness and long-term safety.https://www.tandfonline.com/doi/10.1080/09546634.2025.2451804Livedoid vasculopathyJanus Kinase inhibitorsbiologicstreatmentvascular disease |
| spellingShingle | Yu Liu Tingting Li Wei Shi Janus kinase inhibitors and biologics for treatment of livedoid vasculopathy: a systematic review Journal of Dermatological Treatment Livedoid vasculopathy Janus Kinase inhibitors biologics treatment vascular disease |
| title | Janus kinase inhibitors and biologics for treatment of livedoid vasculopathy: a systematic review |
| title_full | Janus kinase inhibitors and biologics for treatment of livedoid vasculopathy: a systematic review |
| title_fullStr | Janus kinase inhibitors and biologics for treatment of livedoid vasculopathy: a systematic review |
| title_full_unstemmed | Janus kinase inhibitors and biologics for treatment of livedoid vasculopathy: a systematic review |
| title_short | Janus kinase inhibitors and biologics for treatment of livedoid vasculopathy: a systematic review |
| title_sort | janus kinase inhibitors and biologics for treatment of livedoid vasculopathy a systematic review |
| topic | Livedoid vasculopathy Janus Kinase inhibitors biologics treatment vascular disease |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2025.2451804 |
| work_keys_str_mv | AT yuliu januskinaseinhibitorsandbiologicsfortreatmentoflivedoidvasculopathyasystematicreview AT tingtingli januskinaseinhibitorsandbiologicsfortreatmentoflivedoidvasculopathyasystematicreview AT weishi januskinaseinhibitorsandbiologicsfortreatmentoflivedoidvasculopathyasystematicreview |